AUGUST SEMINAR NOTICE

Presented by

Yale School of Medicine's, Department of Therapeutic Radiology

"Radiation Sensitivity in ARID1A Deficiency"

1. Jessie Li, Medical Student
Yale School of Medicine

"Hypofractionated Radiotherapy in Stage I NSCLC and Limited Stage SCLC"

2. Nadia Saeed, Medical Student
Yale School of Medicine

Date: Thursday, August 12, 2021
Location: Zoom Meeting

Course Director/Host: Henry S. Park, MD, MPH
There is no corporate support for this activity
This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
Attending Physicians; Housestaff/Fellows; Medical Students; Nurses; PA's; Other

NEEDS ASSESSMENT
1. ARID1A is a frequently mutated gene in ovarian and endometrial cancers, suggesting this pathway may be a potential therapeutic target, though it is not currently utilized In this manner. The purpose of this conference is to present literature and data to further elucidate ARID1A loss as a biomarker for sensitivity to treatment, in particular to radiation therapy.
2. There is limited U.S. data on HFRT in limited-stage SCLC and currently no consensus regarding fractionation for HFRT in stage I NSCLC [1]. HFRT is likely more convenient and less expensive compared to CFRT. This conference is needed to discuss the role of HFRT in these settings and to help identify select patients who may be candidates for this modality. [1] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (Version 6.2020).

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
1. To understand the role of ARID1A in the DNA damage response and DNA repair mechanism. To identify potential mechanism by which ARID1A deficiency confers radiation sensitivity. To understand implications of increased radiation sensitivity in ARID1A-deficeint tumors.
2. Describe the impact of dose escalation with HFRT on overall survival in stage I NSCLC unsuitable for surgery or SBRT. Compare overall survival with HFRT vs. standard radiotherapy in locally advanced limited-stage SCLC. Discuss how chemotherapy timing effects the relationship between fractionation schedule and overall survival in locally advanced LS-SCLC, and how this information can be used to identify patients who can be considered for HFRT.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 *AMA PRA Category 1 Credit(s)*™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Jessie Li, Med Student – None; Nadia Saeed, Med Student – None; Henry S. Park, MD, MPH –Bristol Myers Squibb, Honorarium, Speaker

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.